Section
This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balanc
Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains
This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immun
Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.
This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.
Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.
A recent trial evaluates the effectiveness of counseling interventions on patient preparedness and sexual outcomes after pelvic surgeries.
A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and re
The ESD 2025 expert consensus updates diagnosis, prevention and interventional care for urinary stones—prioritizing metabolic evaluation, morpho‑compositional stone analysis, pressure/temperature safety in endourology, suction-enabled RIRS,
This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.
A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitori
Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in
A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiot
This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits
This article reviews current evidence from a Cochrane systematic review on vaginal laser therapy for stress urinary incontinence in women, highlighting uncertain efficacy and safety profiles compared to sham and other treatments.
The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transfor
This article reviews microsurgical techniques and patient outcomes in penile replantation, highlighting complications, innovative management strategies, and the critical need for standardized protocols to improve functional and aesthetic re
Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac
